Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron content

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2286-2299

  Kaur, Suneet ^a   Srivastava, Gautam ^a,b   Sharma, Amar Nath ^a   Jolly, Ravinder S ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAERULOMYCIN A; CD71 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEFEROXAMINE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA; FERRITIN; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; IRON; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; IRON CHELATING AGENT; LEUKOCYTE ANTIGEN; PYRIDINE DERIVATIVE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; TRANSFERRIN RECEPTOR;

ARTICLE; CATALYSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DNA SYNTHESIS; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IRON CHELATION; IRON DEPLETION; IRON TRANSPORT; JURKAT CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; S PHASE CELL CYCLE CHECKPOINT; T LYMPHOCYTE;

ANTIGENS, CD; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRON; IRON CHELATING AGENTS; JURKAT CELLS; MAP KINASE SIGNALING SYSTEM; OXIDATIVE STRESS; PYRIDINES; RECEPTORS, TRANSFERRIN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; S PHASE CELL CYCLE CHECKPOINTS; T-LYMPHOCYTES;

EID: 84926648260     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13051     Document Type: Article

References (59)

1. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V, (2004). T cell tolerance and autoimmunity. Autoimmun Rev 3: 471-475.
2. Aisen P, Enns C, Wessling-Resnick M, (2001). Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 33: 940-959.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Ba Q, Hao M, Huang H, Hou J, Ge S, Zhang Z, et al. (2013). Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res 17: 7625-7633.
5. Bianchi V, Pontis E, Reichard P, (1986). Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261: 16037-16042.
6. Brock JH, Mulero V, (2000). Cellular and molecular aspects of iron and immune function. Proc Nutr Soc 59: 537-540.
7. Cerqueira NM, Fernandes PA, Ramos MJ, (2007). Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2: 11-29.
8. Chua AC, Graham RM, Trinder D, Olynyk JK, (2007). The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 44: 413-459.
9. Danesi R, Del Tacca M, (2004). Hematologic toxicity of immunosuppressive treatment. Transplant Proc 36: 703-704.
10. Dhillon AS, Hagan S, Rath O, Kolch W, (2007). MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
11. Dholakia S, Gillard RD, (1984). Equilibria in complexes of N-heterocyclic molecules. Part 34. Iron binding by caerulomycins. J Chem Soc Dalton Trans 1984: 2245-2248.
12. Gahlot S, Khan MA, Rishi L, Majumdar S, (2010). Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 80: 1650-1661.
13. Gurram RK, Kujur W, Maurya SK, Agrewala JN, (2014). Caerulomycin A enhances transforming growth factor-beta (TGF-beta)-Smad3 protein signaling by suppressing interferon-gamma (IFN-gamma)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs). J Biol Chem 289: 17515-17528.
14. Halloran PF, (2004). Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729.
15. Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, et al. (2011). Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS ONE 6: e23800.
16. Heffeter P, Popovic-Bijelic A, Saiko P, Dornetshuber R, Jungwirth U, Voevodskaya N, et al. (2009). Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III) ] trithiocyanate (KP772). Curr Cancer Drug Targets 9: 595-607.
17. Hsu DC, Katelaris CH, (2009). Long-term management of patients taking immunosuppressive drugs. Aust Prescr 32: 68-71.
18. Issa F, Schiopu A, Wood KJ, (2010). Role of T cells in graft rejection and transplantation tolerance. Expert Rev Clin Immunol 6: 155-169.
19. Kalinowski DS, Richardson DR, (2005). The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57: 547-583.
20. Kim BS, Yoon KH, Oh HM, Choi EY, Kim SW, Han WC, et al. (2002). Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell Immunol 220: 96-106.
21. Koc A, Wheeler LJ, Mathews CK, Merrill GF, (2004). Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J Biol Chem 279: 223-230.
22. Kovarik JM, Burtin P, (2003). Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 8: 47-62.
23. Kuvibidila SR, Porretta C, Baliga BS, (2001). Iron deficiency alters the progression of mitogen-treated murine splenic lymphocytes through the cell cycle. J Nutr 131: 2028-2033.
24. Le NT, Richardson DR, (2002). The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603: 31-46.
25. Le NT, Richardson DR, (2003). Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 24: 1045-1058.
26. Leyral C, Beylot-Barry M, Vergier B, Begueret H, Dromer C, Doutre MS, et al. (2008). [Cyclosporine-induced follicular eruption]. Ann Dermatol Venereol 135: 58-62.
27. Lin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, et al. (2007). Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73: 760-772.
28. Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, et al. (2011). Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol 80: 1000-1012.
29. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) ) method. Methods 25: 402-408.
30. Ludwiczek S, Aigner E, Theuri I, Weiss G, (2003). Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101: 4148-4154.
31. MacKenzie EL, Iwasaki K, Tsuji Y, (2008). Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 10: 997-1030.
32. Naesens M, Kuypers DR, Sarwal M, (2009). Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508.
33. Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, et al. (2013). Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol 69: 1659-1665.
34. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
35. Petrak J, Myslivcova D, Man P, Cmejla R, Cmejlova J, Vyoral D, (2006). Proteomic analysis of iron overload in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 290: G1059-G1066.
36. Pierro DD, Tavazz B, Perno CF, Bartolini M, Balestra E, Calio R, et al. (1995). An ion-pairing high-performance liquid chromatographic method for the direct simultaneous determination of nucleotides, deoxynucleotides, nicotinic coenzymes, oxypurines, nucleosides, and bases in perchloric acid cell extracts. Anal Biochem 231: 407-412.
37. Pillans P, (2006). Immunosuppressants-mechanisms of action and monitoring. Aust Prescr 29: 99-101.
38. Ponka P, (1999). Cellular iron metabolism. Kidney Int 55 (Suppl. 69): S2-S11.
39. Raman M, Chen W, Cobb MH, (2007). Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112.
40. Richardson D, Ponka P, Baker E, (1994). The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54: 685-689.
41. Richardson DR, Tran EH, Ponka P, (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306.
42. Rishi L, Gahlot S, Kathania M, Majumdar S, (2009). Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression. Biochem Pharmacol 77: 30-45.
43. Rosenberger J, Geckova AM, Dijk JP, Roland R, Heuvel WJ, Groothof FJ, (2005). Factors modifying stress from adverse effects of immunosuppressive medication in kidney transplant recipients. Clin Transplant 19: 70-76.
44. Sanvisens N, de Llanos R, Puig S, (2013). Function and regulation of yeast ribonucleotide reductase: cell cycle, genotoxic stress, and iron bioavailability. Biomed J 36: 51-58.
45. Shao J, Zhou B, Chu B, Yen Y, (2006). Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6: 409-431.
46. Singla AK, Agrewala JN, Vohra RM, Jolly RS, (2012). Use of bipyridine compound 'Caerulomycin A' derivatives and analogs thereof as immunosuppressive agents. US Patent 8,114,895B2.
47. Singla AK, Gurram RK, Chauhan A, Khatri N, Vohra RM, Jolly RS, et al. (2014). Caerulomycin A: a potent novel immunosuppressive agent. Transplantation 97: e57-e59.
48. Thaci D, Salgo R, (2010). Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 28: 52-56.
49. Tholander F, Sjoberg BM, (2012). Discovery of antimicrobial ribonucleotide reductase inhibitors by screening in microwell format. Proc Natl Acad Sci U S A 109: 9798-9803.
50. Utecht KN, Hiles JJ, Kolesar J, (2006). Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 63: 2340-2348.
51. Weiss G, (2002). Iron and immunity: a double-edged sword. Eur J Clin Invest 32 (Suppl. 1): 70-78.
52. Weiss G, (2005). Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol 18: 183-201.
53. Whitnall M, Howard J, Ponka P, Richardson DR, (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103: 14901-14906.
54. Wu MS, (2007). From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells. Chang Gung Med J 30: 7-16.
55. Yu Y, Richardson DR, (2011). Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem 286: 15413-15427.
56. Yu Y, Kovacevic Z, Richardson DR, (2007). Tuning cell cycle regulation with an iron key. Cell Cycle 6: 1982-1994.
57. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, et al. (2009). Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52: 5271-5294.
58. Yuan J, Lovejoy DB, Richardson DR, (2004). Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104: 1450-1458.
59. Zelenika D, Adams E, Humm S, Lin CY, Waldmann H, Cobbold SP, (2001). The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev 182: 164-179.